164 related articles for article (PubMed ID: 29707001)
1. Experience and Expectations of Ovarian Cancer Patients in Australia.
Holliday CM; Morte M; Byrne JM; Holliday AT
J Oncol; 2018; 2018():7863520. PubMed ID: 29707001
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
4. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP; Monk BJ; Han S; Pothuri B; Auranen A; Chase DM; Lorusso D; Anderson C; Abadie-Lacourtoisie S; Cloven N; Braicu EI; Amit A; Redondo A; Shah R; Kebede N; Hawkes C; Gupta D; Woodward T; O'Malley DM; González-Martín A
Ther Adv Med Oncol; 2022; 14():17588359221126149. PubMed ID: 36172173
[TBL] [Abstract][Full Text] [Related]
5. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
6. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
7. What Do Ovarian Cancer Patients Expect From Treatment?: Perspectives From an Online Patient Community.
Simacek K; Raja P; Chiauzzi E; Eek D; Halling K
Cancer Nurs; 2017; 40(5):E17-E27. PubMed ID: 27454765
[TBL] [Abstract][Full Text] [Related]
8. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.
Mertz S; Benjamin C; Girvalaki C; Cardone A; Gono P; May SG; Comerford E; Than KS; Birch K; Roach M; Myers S; Sasane M; Lavi L; Cameron A; Cardoso F
Breast; 2022 Oct; 65():84-90. PubMed ID: 35870420
[TBL] [Abstract][Full Text] [Related]
10. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
11. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Osann K; Wenzel L; McKinney C; Wagner L; Cella D; Fulci G; Scroggins MJ; Lankes HA; Wang V; Nephew KP; Maxwell GL; Mok SC; Conrads TP; Miller A; Birrer M
Gynecol Oncol; 2023 Apr; 171():151-158. PubMed ID: 36905875
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
15. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study.
Wenzel LB; Donnelly JP; Fowler JM; Habbal R; Taylor TH; Aziz N; Cella D
Psychooncology; 2002; 11(2):142-53. PubMed ID: 11921330
[TBL] [Abstract][Full Text] [Related]
16. Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial.
Kvale E; Phillips F; Ghosh S; Lea J; Hoppenot C; Costales A; Sunde J; Badr H; Nwogu-Onyemkpa E; Saleem N; Ward R; Balasubramanian B
JMIR Res Protoc; 2024 Feb; 13():e48069. PubMed ID: 38335019
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
18. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
[TBL] [Abstract][Full Text] [Related]
19. Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study.
Jenkins V; Catt S; Banerjee S; Gourley C; Montes A; Solis-Trapala I; Monson K; Fallowfield L
Br J Cancer; 2013 Jun; 108(11):2264-71. PubMed ID: 23652312
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
